Additionally, we found that GPR176 expression was negatively associated with male sex, T staging, Her-2 positivity, and mutant p53 status of breast cancer, in line with the positive relationship between GPR176 methylation and pathological stage, and immunohistochemical findings. The gene discussed is ERBB2; the disease is breast cancer.